Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07039526 · ClinicalTrials.gov registry record · Phase 2
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
A Phase 2 study of Esophageal Cancer and Gynecologic Cancers, sponsored by John Waters.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07039526 is a Phase 2 study of Esophageal Cancer and Gynecologic Cancers that is actively recruiting participants, run by John Waters. The registered enrollment target is 50 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07039526, a Phase 2 study of Esophageal Cancer and Gynecologic Cancers, is actively recruiting participants, sponsored by John Waters.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of clinical trial is to test an FDA approved drug called Pafolacianine that attaches to cancer cells and lights up when seen through a special camera system in adults with a suspected primary diagnosis, or a high clinical suspicion of gastrointestinal, fore gut, pancreatic, hepatobiliary, esophageal malignancies and gyn malignancies planned for HIPEC/debulking, warranting surgery. The main question it aims to answer is: • Can CYTALUX™ (pafolacianine) injection used with near-infrared (NIR) fluorescent imaging improve the detection of malignant tissue in subjects undergoing surgical resection for cancer? Participants taking part in this study will receive the study medication. Then, during the surgery the investigator team will turn on the camera to evaluate if the tumor is visible with the help of the study medication. Taking part in this study will last about 2 months.
Conditions Studied
Interventions
- DRUG CYTALUX™ (pafolacianine) injection preoperatively
Study Locations (1)
Texas
- Clemments University Hospital - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-08-19 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07039526
The ClinicalTrials.gov registry entry for NCT07039526 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (90% lower). The listed sponsor is John Waters, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 1 intervention - of which CYTALUX™ (pafolacianine) injection preoperatively is the first listed.
NCT07039526 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07039526 about?
NCT07039526 is a clinical study titled "Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.". The goal of clinical trial is to test an FDA approved drug called Pafolacianine that attaches to cancer cells and lights up when seen through a special camera system in adults with a suspected primary diagnosis, or a high clinical suspicion of gastrointestinal, fore gut, pancreatic, hepatobiliary, e...
What is the current status of trial NCT07039526?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-08-19. Estimated completion is 2027-12.
What conditions does trial NCT07039526 study?
This clinical trial studies the following conditions: Esophageal Cancer, Gynecologic Cancers, Gastrointestinal Cancers.
What interventions are being tested in trial NCT07039526?
The interventions under investigation include: CYTALUX™ (pafolacianine) injection preoperatively (DRUG).
Who is sponsoring clinical trial NCT07039526?
This trial is sponsored by John Waters, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07039526 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
-
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.